Ductal Carcinoma in Situ Therapy
Research from University of Southern California, Norris Comprehensive Cancer Center has provided new information about ductal carcinoma in situ therapy
Published in Oncology Business Week, December 3rd, 2006
Fresh data on ductal carcinoma in situ are presented in the report "Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. A previous study showed a 3% local recurrence risk at 8 years in ductal carcinoma in situ (DCIS) patients treated with excision alone with surgical margins of 10 mm or greater. This study updates those data," scientists in the United States report.
"A total of 272 DCIS patients treated conservatively with 10 mm or greater margins were reviewed in a prospective database. Among 212 excision-alone patients, there were 9 DCIS and 3 invasive recurrences. The 12-year...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Acute Myeloid Leukemia
Lorus Therapeutics announces presentation on GTI-2040 uptake by tumor cells in AML - Brain Cancer
Northwest Biotherapeutics discusses results from clinical trials in brain cancer - Breast Cancer
Bionovo's phase I/II trial protocol for metastatic breast cancer accepted by U.S. FDA - Breast Cancer
Komen Foundation joins U.S. State Department to launch breast cancer initiative in Middle East - Breast Cancer Vaccine
BN ImmunoTherapeutics reports data on breast cancer vaccine shows exceptional efficacy - Business & Finance
Callisto Pharmaceuticals closes on preferred stock financing - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
